Overview

Topotecan Plus Cisplatin Versus Etoposide Plus Cisplatin In 1st Line Extensive Disease Small Cell Lung Cancer

Status:
Completed
Trial end date:
2007-02-01
Target enrollment:
Participant gender:
Summary
Evaluation of intravenous Topotecan + Cisplatin as a potential new standard of care in 1st line Small Cell Lung Cancer
Phase:
Phase 3
Details
Lead Sponsor:
GlaxoSmithKline
Treatments:
Cisplatin
Etoposide
Etoposide phosphate
Topotecan